Article Versions Notes

Rabie ASI, Salah H, Said ASA, Shaaban AH, Abdou LM, Khalil DM, Kharaba Z, Afifi H, Sofy MR, Youssef EMI, et al. Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection. Healthcare. 2023; 11(4):607. https://doi.org/10.3390/healthcare11040607

Rabie, Al Shaimaa Ibrahim, Hager Salah, Amira S. A. Said, Ahmed Hassan Shaaban, Lamya Mohamed Abdou, Doaa Mahmoud Khalil, Zelal Kharaba, Hala Afifi, Mahmoud R. Sofy, Eman M. I. Youssef, and et al. 2023. "Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection" Healthcare 11, no. 4: 607. https://doi.org/10.3390/healthcare11040607

Rabie, A. S. I., Salah, H., Said, A. S. A., Shaaban, A. H., Abdou, L. M., Khalil, D. M., Kharaba, Z., Afifi, H., Sofy, M. R., Youssef, E. M. I., Bayoumy, E. S. M., & Hussein, R. R. S. (2023). Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection. Healthcare, 11(4), 607. https://doi.org/10.3390/healthcare11040607